Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : published form 20-F for the fiscal year 2019

share with twitter share with LinkedIn share with facebook
02/21/2020 | 07:00am EDT

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous
Fresenius Medical Care published form 20-F for the fiscal year 2019

21.02.2020 / 11:54
The issuer is solely responsible for the content of this announcement.



Fresenius Medical Care, the world's largest provider of dialysis products and services, has filed the annual report 2019 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website (freseniusmedicalcare.com) in the "Investors" section as well as at the SEC's website (www.sec.gov).

A hard copy of Fresenius Medical Care's annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request to the company's Investor Relations department by email at ir@fmc-ag.com.

The company also published a Facts & Figures 2019 website at factsandfigures.fmc-ag.com to provide an overview of the key financial figures for the fiscal year 2019. In addition, the new Corporate Magazine, Company Profile as well as a Five-Year-Summary are available for download.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com and factsandfigures.fmc-ag.com.

Disclaimers
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.




 


21.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.freseniusmedicalcare.com
ISIN: DE0005785802
WKN: 578580
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID: 980927

 
End of News DGAP News Service

980927  21.02.2020 

fncls.ssp?fn=show_t_gif&application_id=980927&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
02:15pFRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
EQ
10:25aFRESENIUS SE : Berenberg maintains a Buy rating
MD
09:27aFMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg reiterates its Buy rating
MD
08:58aFMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from UBS
MD
08:24aFMC FRESENIUS MEDICAL CARE AG & CO K : Warburg Research sticks Neutral
MD
08:06aFRESENIUS SE : Warburg Research remains its Buy rating
MD
08:01aFRESENIUS SE : Barclays keeps its Buy rating
MD
07:45aFRESENIUS SE : Goldman Sachs remains its Buy rating
MD
07:15aFMC FRESENIUS MEDICAL CARE AG & CO K : Kepler Cheuvreux remains its Buy rating
MD
06:59aFMC FRESENIUS MEDICAL CARE AG & CO K : Bernstein reiterates its Neutral rating
MD
More news
Financials (USD)
Sales 2020 21 506 M - -
Net income 2020 1 548 M - -
Net Debt 2020 14 274 M - -
P/E ratio 2020 14,6x
Yield 2020 1,83%
Capitalization 22 634 M 22 604 M -
EV / Sales 2020 1,72x
EV / Sales 2021 1,61x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 96,61 $
Last Close Price 77,29 $
Spread / Highest target 48,5%
Spread / Average Target 25,0%
Spread / Lowest Target -17,7%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors